Loading data for IMVT — first visit, this takes a few seconds.

提醒

Immunovant Inc. (IMVT)

NasdaqGS: IMVT · 即時價格 · USD

41.20

-2.62 (-5.98%)

收盤價： Aug 28, 2026, 3:59 PM

40.58

-1.50%

盤後: 7:30 PM

股價、關鍵數字和最新消息，都在這一頁。

-5.98% (1D)

買價	30.83
市值	8.51B
營收 (ttm)	n/a
淨利（ttm）	-538.22M
	0.81
	-2.64
	n/a
	-14.98
P/B (ttm)	11.56
P/S (ttm)	n/a
財報日期	Nov 9, 2026

賣價	52.71
成交量	1,082,320
20 日平均成交量	1,287,369
開盤價	43.27
前收盤價	43.82
當日區間	41.09 - 43.38
52 週範圍	14.58 - 45.42
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 IMVT

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Jun 21, 2019

員工 315

證券交易所 NasdaqGS

股票代號 IMVT

網站 https://immunovant.com

完整的公司簡介

財務表現

Immunovant 在 2026 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -505.61M，較前期增加 22.17%。

財務報表

財報驚奇

Immunovant 已於 Aug 6, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.68 低於預期 -0.07, 年增 4.23% 成長.

下次財報發布

Immunovant Inc. 的下次財報預計於 Nov 9, 2026, 開盤前。
分析師預估營收 ... 升級

新聞動態

5 天前 · MT Newswires

Immunovant's Risk/Reward Profile Balanced After Recent Rally, UBS Says

Immunovant (IMVT) has broad diversification with encouraging updates but faces balanced risk/reward

2 週前 · Motley Fool

Immunovant (IMVT) Q1 2027 Earnings Call Transcript

CEO signals multiple pivotal data readouts ahead as cash runway supports IMVT-1402 development.

3 週前 · MarketBeat

Roivant Sciences Q1 Earnings Call Highlights

Roivant Sciences (NASDAQ:ROIV) said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions a...

3 週前 · Moby

Immunovant, Inc. Q1 2027 Earnings Call Summary

Moby summary of Immunovant, Inc.'s Q1 2027 earnings call

3 週前 · MarketBeat

Immunovant Q1 Earnings Call Highlights

Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple...

第 1 頁，共 2 頁

Immunovant Inc. (IMVT)